[DOI] [PubMed] [Google Scholar] 21.Canapp SO, Jr, Farese JP, Schultz GS, Gowda S, Ishak AM, Swaim SF, Vangilder J, Lee-Ambrose L, Martin FG
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records
Cons Its more expensive than some similar brands
As a compounded medication, this product is not evaluated by the United States Food and Drug Administration for safety or efficacy, and clinical use should therefore be guided by careful patient selection, informed consent, and ongoing monitoring to ensure that the lowest effective dose is employed for the shortest duration compatible with therapeutic goals